광선각화증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료법별, 약제클래스별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Actinic Keratosis Treatment Market will grow from USD 6.92 Billion in 2024 to USD 9.25 Billion by 2030 at a 4.95% CAGR. The global actinic keratosis (AK) treatment market encompasses pharmaceutical interventions, such as topical medications and photodynamic therapy, alongside procedural approaches like cryotherapy and surgical excision, all aimed at addressing precancerous skin lesions primarily induced by chronic ultraviolet exposure.

Key Market Drivers

The global actinic keratosis treatment market is significantly propelled by the rising prevalence of actinic keratosis and the aging global population. The increasing incidence of actinic keratosis directly expands the patient pool requiring diagnosis and therapeutic intervention. According to the British Journal of Dermatology, March 2024, in "Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis", the global prevalence rate for actinic keratosis is 14%, indicating a substantial disease burden worldwide.

Key Market Challenges

The persistent lack of skilled dermatology specialists and qualified healthcare providers significantly impedes the growth of the global actinic keratosis treatment market. This shortage directly limits treatment penetration and causes substantial delays in patient care. Across various regions, the inadequate availability of specialists means fewer individuals receive timely diagnosis and appropriate therapeutic interventions for precancerous skin lesions.

Key Market Trends

The emergence of novel topical and systemic therapies significantly drives the global actinic keratosis treatment market by introducing advanced agents with improved efficacy, reduced side effects, and innovative mechanisms of action. These new treatments often address limitations of existing options, providing dermatologists with a broader range of choices for tailored patient care and potentially higher clearance rates.

Key Market Players

• Almirall S.A.
• LEO Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GALDERMA SA
• Ortho Dermatologics (Bausch Health Companies Inc.)
• BIOFRONTERA AG
• Hill Dermaceuticals, Inc.

Report Scope:

In this report, the Global Actinic Keratosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Actinic Keratosis Treatment Market, By Therapy:

• Topical
• Surgery
• Photodynamic Therapy

Actinic Keratosis Treatment Market, By Drug Class:

• Nucleoside metabolic inhibitor
• NSAIDS
• Immune response modifiers
• Photoenhancers
• Others

Actinic Keratosis Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Actinic Keratosis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Actinic Keratosis Treatment Market.

Available Customizations:

Global Actinic Keratosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Actinic Keratosis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Topical, Surgery, Photodynamic Therapy)
  • 5.2.2. By Drug Class (Nucleoside metabolic inhibitor, NSAIDS, Immune response modifiers, Photoenhancers, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Actinic Keratosis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Drug Class
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Actinic Keratosis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Actinic Keratosis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Actinic Keratosis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By End User

7. Europe Actinic Keratosis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Drug Class
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Actinic Keratosis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By End User
  • 7.3.2. France Actinic Keratosis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Actinic Keratosis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Actinic Keratosis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Actinic Keratosis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By End User

8. Asia Pacific Actinic Keratosis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Drug Class
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Actinic Keratosis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By End User
  • 8.3.2. India Actinic Keratosis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Actinic Keratosis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Actinic Keratosis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Actinic Keratosis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By End User

9. Middle East & Africa Actinic Keratosis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Drug Class
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Actinic Keratosis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Actinic Keratosis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Actinic Keratosis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By End User

10. South America Actinic Keratosis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Drug Class
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Actinic Keratosis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Actinic Keratosis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Actinic Keratosis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Actinic Keratosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Almirall S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. LEO Pharma A/S
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Novartis AG
• 15.5. GALDERMA SA
• 15.6. Ortho Dermatologics (Bausch Health Companies Inc.)
• 15.7. BIOFRONTERA AG
• 15.8. Hill Dermaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer